Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who will derive the optimal benefit from established and emerging therapies. Real-world data provide crucial insight into practice patterns and response rates, ultimately guiding individualization of treatment selection. In this activity, expert faculty assess key findings from prostate and bladder cancer trials and explore the relevance of these data to clinical practice.